Amoeba SA ( (FR:ALMIB) ) has shared an update.
Amoéba is expanding its production capacities at its Chassieu site to support the commercial launch of its biocontrol product range ‘AXPERA.’ Following a memorandum of understanding with Koppert and positive conclusions from EFSA, the company is preparing for market authorizations and sales. The €1.1 million investment will enhance production capacity, streamline processes, and reduce costs. Amoéba is also exploring further capacity increases through industrial investments, partnerships with CDMOs, and collaboration with Koppert, positioning itself for growth in the biocontrol market.
More about Amoeba SA
Amoéba is a greentech company based in Chassieu, France, specializing in microbiological solutions using amoebas for plant protection and cosmetics. Founded in 2010, it aims to replace chemical products with biological alternatives and is the only company capable of industrial-scale amoeba exploitation. It operates in the global biocontrol and cosmetic markets, with its products subject to regulatory approvals.
YTD Price Performance: -12.21%
Average Trading Volume: 2,395
Technical Sentiment Consensus Rating: Hold
Current Market Cap: €39.83M
Learn more about ALMIB stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com